secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adagio Medical Holdings, Inc. (ADGM)
CIK:        0002006986
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001104659-26-035699
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adagio Medical reports FY2025 net loss $25.1M; FULCRUM-VT trial fully enrolled with 97% acute effectiveness
--------------------------------------------------------------------------------

- Net loss of $25.1M for FY2025, down from $75.0M in FY2024; Q4 net loss $3.3M vs $57.4M.
- Completed enrollment of 209-patient FULCRUM-VT pivotal IDE trial; preliminary 97% acute effectiveness.
- Closed private placement with gross proceeds up to $50M; upfront $19M to fund FDA submission.
- Cash and equivalents $17.1M as of Dec 31, 2025; no revenue reported.
- Appointed former Medtronic executive Sean Salmon to Board; added senior sales and manufacturing VPs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2006986/000110465926035699/0001104659-26-035699-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2006986/000110465926035699/adgm-20260326x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-035699

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer